FUSCC Refractory TNBC Platform Study (FUTURE2.0)
Fudan University
Fudan University
M.D. Anderson Cancer Center
Kivu Bioscience Inc.
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Exelixis
Shanghai Junshi Bioscience Co., Ltd.
Wake Forest University Health Sciences
Mersana Therapeutics
Cellectar Biosciences, Inc.
Stanford University
Bristol-Myers Squibb
AbbVie
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)
UNC Lineberger Comprehensive Cancer Center
Beijing Biotech
Yonsei University
Novartis
Fudan University
Exscientia AI Limited
Genmab
University of Washington
Royal Marsden NHS Foundation Trust
Epsilogen Ltd
Beijing Biotech
The Methodist Hospital Research Institute
National Cancer Institute (NCI)
Swiss Cancer Institute
Zumutor Biologics Inc.
Cedars-Sinai Medical Center
H. Lee Moffitt Cancer Center and Research Institute
Universitaire Ziekenhuizen KU Leuven
H. Lee Moffitt Cancer Center and Research Institute
Sun Yat-sen University
Bristol-Myers Squibb
IDEAYA Biosciences
SillaJen, Inc.
University of Iowa
Radiopharm Theranostics, Ltd
Fudan University
Eli Lilly and Company
National Institutes of Health Clinical Center (CC)
Universitaire Ziekenhuizen KU Leuven
Beijing Biotech
Brigham and Women's Hospital